The Angers University Hospital announced on Tuesday the launch of a vast survey “with the highest scientific and methodological standards”, involving 1,300 patients with covid-19, to find out the effectiveness of a chloroquine derivative .

The Angers University Hospital announced on Tuesday the launch of a vast survey “with the highest scientific and methodological standards”, involving 1,300 patients with covid-19, to find out the effectiveness of a chloroquine derivative .

(.) – “This is a study that meets the highest scientific and methodological standards. It will be carried out under conditions which will not leave room for doubt in the analysis of the results, ”underlined Professor Vincent Dubée, principal investigator of the project, during a press briefing.

Professor Didier Raoult has published two studies on a derivative of chloroquine, which confirm, according to him, the “effectiveness” of this treatment against the coronavirus, but this assertion is disputed by many scientists, who criticize in particular the methodology used.

Blind study

Angevin research, called Hycovid and carried out with 32 other hospitals in France, “will allow us to answer these questions definitively and to close once and for all the debate on the efficacy of hydroxychloroquine”, (derived from chloroquine , a drug against malaria) in the covid “, assured Professor Dubée.

“We have a neutral position vis-à-vis this molecule. Obviously, we all have great hope that this molecule will be active in the covid. Nevertheless, we are aware of the limits of the results of the studies published by Professor Raoult’s team. We do not have a priori, we did not participate in the media uproar around this molecule. ”

If some people want to generalize the antimalarial chloroquine as a treatment against the covid-19 pandemic, health authorities, including the WHO, call for caution. Update on the state of current knowledge on this substance.

The Hycovid study, which is due to start on Wednesday April 1, will be double-blind: neither patients nor doctors will know if the patient is receiving chloroquine or a placebo. Half of the patients will receive a placebo, the other half of chloroquine. They will be patients aged 75 years or more or patients needing oxygen without being “in acute respiratory distress”. Patients can be hospitalized, residents of a nursing home or simply at home.

“One of the strengths of this study is that it will include patients with a non-serious form of the disease but at high risk for an unfavorable course, like certain elderly people. We will therefore treat people early, which is probably a determining factor in the success of treatment, “said Professor Dubée. The first results of this study should be known in a few weeks.

Follow us on Facebook, Twitter and subscribe to our 5pm newsletter.

On the same subject

Chloroquine, miracle treatment or false hope?

If some people want to generalize the antimalarial chloroquine as a treatment against the covid-19 pandemic, health authorities, including the WHO, call for caution. Update on the state of current knowledge on this substance.

LEAVE A REPLY

Please enter your comment!
Please enter your name here